Atherosclerotic renal artery stenosis (ARAS) is the commonest cause of secondary hypertension and is the cause of end stage renal failure in up to 20% of patients starting dialysis. Associated with it is a high morbidity and appalling mortality. The aetiology of ischaemic nephropathy is complex and is not simply related to renal artery narrowing. Captopril renography is sensitive and specific for diagnosing ARAS in patients with normal renal function. In those with renal impairment gadolinium-enhanced MRA or spiral CT angiography clearly define renal anatomy. Over 80% of ARAS is
Introduction
Atherosclerotic renal artery stenosis (ARAS) is the commonest cause of secondary hypertension. The prevalence of atheromatous renovascular hypertension (RVH) is reported to be 1-5%, 1 rising to 30% in those presenting with malignant phase. 2 Where critical stenoses subtend the whole renal mass (bilateral disease or stenosis of a solitary functioning kidney) ARAS may lead to progressive ischaemic renal failure. 3 Prospective renal angiographic studies in patients starting dialysis over the age of 50 indicate ARAS to be the cause in 10-20% of cases. 4 Furthermore, it is implicated in a similar proportion of patients presenting with acute renal failure, usually in association with the introduction of angiotensin-converting enzyme inhibitors. 4 In our aging population with falling coronary mortality, the prevalence of ARAS is rising. 4 Is ARAS worth diagnosing? The answers to the following questions should help us decide.
Is stenosis the main problem?
A 'significant' stenosis is defined as luminal narrowing of greater than 50% in most studies. 5, 6 This definition probably greatly overestimates the prevalence of renovascular hypertension and ischaemic renal failure due to ARAS. Renal autoregulation maintains constant renal blood flow down to a mean perfusion pressure of 70-80 mm Hg, usually corre- sponding to a stenosis of 70-80%. 7 Renal oxygen delivery is far in excess of demand and therefore true ischaemia is likely only with near occlusive stenosis. In support of this, ipsilateral kidney function does not differ from the contralateral side in patients with unilateral ARAS. 8 Examination of renal histology in patients with ARAS gives clues to other mechanisms involved. 7 Small vessel plugging from atheremboli is common. Marked intrarenal arterial narrowing and pre-existing hypertensive nephrosclerosis frequently coexist. Nevertheless, by analogy with fibromuscular disease, stenosis can cause hypertension and renal artery occlusion in patients with ARAS almost always leads to loss of renal function. 
Is ARAS progressive?
ARAS is progressive and associated with loss of renal function. A large retrospective angiographic study reported that 44% of the renal artery stenoses progressed, 16% to occlusion, over a mean period of 52 months. High-grade stenosis (greater than 75%) represented an imminent risk to renal function with 39% progressing to occlusion over 13 months. 9 The rate of progression is surprisingly linear at 4 -12%/year. 9, 10 Recently the use of duplex ultrasound has provided prospective data on the natural history of ARAS. Progression from Ͻ60% stenosis to 60% or greater was 23% over 1 year and 42% at 2 years. Of those with Ͼ60% stenosis initially, 5 and 11% subsequently occluded the renal artery by 1 and 2 years respectively. 11 Renal atrophy (Ͼ1 cm decrease of renal length) occurs in 21% of kidneys with greater than 60% renal artery stenosis at baseline and is associated with loss of renal function.
Decline in renal function in patients with ARAS is dependent on the initial angiographic findings. At 2 years, 3% of patients with unilateral stenosis will have reached end stage renal failure (ESRF) as compared with 18% of those with bilateral ARAS and 55% of those with renal artery occlusion and contralateral stenosis. 13 However, the rate of decline in renal function is variable and not linear. Many patients with severe bilateral ARAS maintain stable renal function over 5 years although the median annual loss of GFR is 4 (1-8) ml/min with a cumulative requirement for dialysis of 30%. 14 
Can we screen for it?
In order to identify patients with significant ARAS who may benefit from intervention one must have a screening test that is non-invasive, sensitive and specific. The gold standard test is intra-arterial digital subtraction angiography. However, there are risks associated with the use of contrast and of arterial puncture. Captopril renography is non-invasive and may define functional significance. The sensitivity and specificity is high for detecting unilateral ARAS (Ͼ90%) but its usefulness is markedly reduced in the presence of renal impairment and bilateral disease. 15 Spiral CT and gadolinium-enhanced magnetic resonance angiography (MRA) are both noninvasive and provide excellent images of the renal arteries. The sensitivity and specificity of both tests for the detection of ARAS is in excess of 90%. Spiral CT angiography requires large volumes of intravenous contrast with the risk of nephropathy in patients with impaired renal function. Gadolinium is not nephrotoxic and MRA may provide information on renal function and trans-stenotic pressure gradients. 16 
Does ARAS independently predict patient mortality?
Patients with ARAS frequently have evidence of widespread atherosclerotic disease. Prospective studies of renal angiography have been performed at the same time as angiography for symptomatic atheromatous vascular disease elsewhere. The prevalence of significant ARAS is 45-59%, 28-38%, and 15-23% in patients investigated for peripheral vascular, aorto-occlusive, and coronary artery disease respectively. 4 Not surprisingly, cardiovascular mortality in these patients is very high. ARAS is an independent risk factor for mortality which correlates with the number and severity of renal arteries stenosed. 17 Hypertensive patients with ARAS have a 5 and 10 year survival rate, 10% less than those with essential hypertension. 18 For those with renal impairment due to ARAS the survival is appalling. The probability of survival at 3 years being 92% with normal renal function, 74% with mild and 52% in those with more severe renal failure. 19 Survival on dialysis is worse than for any other patient group. At 2 years nearly half will have died and at 5 years only 12% will be alive. 4 By extrapolation from other high risk patient groups one might anticipate a significant benefit by aggressive treatment of known cardiovascular risk factors such as hypertension and elevated plasma lipids.
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Does revascularisation beneficially affect hypertension or renal failure?
ARAS is a disease of the aorta. In over 80% of cases the stenosis is produced by encroachment of aortic atheromatous plaques at the renal artery ostium (within 1 cm of aortic lumen). 22 Thirty percent are bilateral. 3 Not surprisingly this impacts on the success and complication rates of attempted revascularisation. In major centres surgical revascularisation is associated with a 95% technical success. Perioperative mortality in this elderly atherosclerotic population is significant at 2.5-6%. 3 In view of this, percutaneous transluminal renal artery angioplasty (PTRA) was introduced. PTRA successfully dilates non-ostial ARAS in 75-94% of cases with a 1 year restenosis rate of 10-30%. 23 For the more frequent ostial lesions initial success is achieved in only half (due to elastic recoil) with half of these restenosing within 6 months. 24 These technical problems have been overcome by the use of endoluminal stents. Several series report initial technical success of over 90% with less than 20% restenosis over 2 years. 5, 19, [24] [25] [26] A clear benefit of revascularisation over medical management of atheromatous renovascular hypertension has not been demonstrated. Ramsay reviewed 10 uncontrolled series of PTRA for atheromatous RVH. Hypertension was cured in only 19% and improved (reduced number of antihypertensives) in 52%. 27 It has been argued that low technical success of PTRA explains the poor results. However, the results of three recent trials of renal artery stenting in 231 patients are no better. Stenting cured hypertension in 0-16%, with improvement (mean reduction of half of one hypotensive drug) in around half of patients. 19, 25, 26 Even the modest improvement in blood pressure may be overestimated in these uncontrolled studies as recorded blood pressure in patients with RVH spontaneously falls with follow up. 28 Three prospective randomised controlled trials comparing PTRA +/− stenting have recently reported. The Scottish and Newcastle study followed 55 patients randomised to PTRA (36% restenosis) or medical therapy. No patient was cured. Angioplasty resulted in a modest reduction in systolic blood pressure in those patients with bilateral atheromatous stenosis. Major procedural complications occurred in 20%. 28 The EMMA study group randomised 49 patients with proven haemodynamically significant ARAS to PTRA +/− stent or medical treatment. At 6 months blood pressure did not differ between the groups although median number of antihypertensive drugs fell by 0.8 per patient in the intervention group. 29 Similarly, the Dutch Renal Artery Stenosis Intervention Cooperative Study found no benefit of intervention on blood pressure at 3 months. 6 The reasons for lack of blood pressure response are unclear but probably include pre-existing essential hypertension, inclusion of patients with incidental ARAS, renal impairment and failure of reversal of long standing adaptive arterial changes.
In recent years the focus of attention has moved to revascularisation as a means of halting the progression of ischaemic renal failure due to severe bilateral ARAS. Prevention of dialysis has major resource and quality of life implications. In selected cases renal revascularisation undoubtedly improves renal function. Hansen et al 30 reports 20 patients with bilateral renal artery occlusion who recovered dialysis independent renal function following surgical treatment. Renal parenchymal viability was maintained by collateral blood supply. 30 A recent review of eight surgical series indicated postoperative improvement in renal function in around half. 3 Despite the high rate of restenosis PTRA may also be of benefit. In a review of six series improvement and stabilisation of renal function occurred in 40 and 30% of patients respectively. 3 Major complications occurred in 3-10% and procedural mortality was 1-3%. In patients with renal failure renal artery stenting results in durable technical success. Two recent studies of renal artery stenting demonstrate significant slowing of the rate of progression of CRF up to 4 years. 5, 19 Some factors appear to be predictive of stabilisation or improvement in renal function following revascularisation. These include a rapid decline in renal function and preoperative serum creatinine less than 300 mol/l. Preintervention renal biopsy has been used by some to assess the degree of irreversible parenchymal damage. Assessment of individual renal function may guide the appropriate kidney to revascularise. This may be important as there seems to be a discrepancy between renal size and function. 31 Interventional treatment for ARAS may have effects beyond the kidney. 'Flash' pulmonary oedema may occur in patients with severe bilateral ARAS despite normal left ventricular function and is cured by adequate revascularisation. 32 A recent report of improved angina and heart failure status in patients undergoing renal artery stenting for ARAS is intriguing. 33 Morbidity related to the stenosis in patients with atheromatous renovascular disease has probably been overestimated. Identification should lead to aggressive cardiovascular risk factor intervention in an attempt to reduce the appalling associated mortality. 'Flash' pulmonary oedema merits revascularisation. However, it appears that intervention for atheromatous RVH is a drug sparing exercise with a significant complication rate and should be reserved for those patients with truly drug resistant hypertension. Percutaneous stenting prevents occlusion and will hopefully reduce the need for dialysis in selected patients although the results of randomised controlled trials are awaited.
